SCHEMBL24210299

SCHEMBL24210299

NNC(=O)c1cc(F)ccc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.63
FADS1 O60427 1/20 0.55
HDAC1 Q13547 5/20 0.45
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
ALDH1A1 P00352 3/20 0.43
GFER P55789 1/20 0.43
ALPL P05186 1/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
BRAF P15056 1/20 0.41
CTSD P07339 2/20 0.41
HDAC6 Q9UBN7 1/20 0.41
MEN1 O00255 1/20 0.41
MITF O75030 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
NCOA1 Q15788 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL690577 0.83 KEAP1 (0.61) KEAP1FADS1HDAC1CES2CES1
SCHEMBL246382 0.82 CES2 (0.61) KEAP1FADS1HDAC1CES2CES1
SCHEMBL29520286 0.82 KEAP1 (0.56) KEAP1FADS1HDAC1CES2CES1
SCHEMBL13753884 0.82 KEAP1 (0.56) KEAP1FADS1HDAC1CES2CES1
SCHEMBL7698671 0.81 KEAP1 (0.54) KEAP1FADS1HDAC1CES2CES1
SCHEMBL15630978 0.81 KEAP1 (0.59) KEAP1FADS1HDAC1MAPTKDM4E
SCHEMBL1639721 0.81 P2RX1 (0.54) KEAP1CES2CES1ALDH1A1GFER
SCHEMBL1559256 0.80 KEAP1 (0.58) KEAP1FADS1HDAC1CES2CES1
SCHEMBL2700198 0.80 MAPT (0.59) FADS1ALDH1A1GFERMAPTKDM4E
SCHEMBL22466424 0.79 F2R (0.51) KEAP1CES2CES1ALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017524-A1 ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS THE BROAD INSTITUTE, INC. (US) 2022-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220017524-A1 ARYL HYDROCARBON RECEPTOR (AHR) ACTIVATOR COMPOUNDS AS CANCER THERAPEUTICS AHR, ESRRA, AR KEAP1 868/4885FADS1 278/4885HDAC1 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.